Skip to content

Low dose amoxycillin versus amoxycillin and probenecid for syphilis in HIV patient: a randomised, open-label, non-inferiority trial

Low dose amoxycillin versus amoxycillin and probenecid for syphilis in HIV patient: a randomised, open-label, non-inferiority trial - Low dose amoxycillin versus amoxycillin and probenecid for syphilis in HIV patient: a randomised, open-label, non-inferiority trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000033986
Enrollment
112
Registered
2018-09-03
Start date
2018-09-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syphilis

Interventions

amoxycillin 500 mg orally three times a day 14 days for early syphilis(primary, secondary and early latent syphilis) 28 days for late syphilis(late latent syphilis and unknown duration of syphil

Sponsors

self-finance
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) HIV patient 2) The diagnosis of syphilis was based on a) or b) a) Serum rapid plasma regain(RPR) titers is 8 or greater and positive Treponema. Pallidum Hemagglutination(TPHA) result. When serum RPR titers is 8, the diagnosis of syphilis requires signs of syphilis like chancre or skin rash. b) 4-fold or more rise in RPR titer from the individual's prior test

Exclusion criteria

Exclusion criteria: 1) pregnant or breast feeding woman 2) a history of amoxycillin or probenecid allergy 3) otosyphilis, ocular syphilis or neurosyphilis diagnosed based on the findings of cerebrospinal fluid 4) patient who needs antibiotics other than the antibiotics we used in this study which is effective for syphilis at diagnosis 5)patient who started antibiotics within 3 weeks before diagnosis

Design outcomes

Primary

MeasureTime frame
Treatment success rate at one year after treatment

Secondary

MeasureTime frame
Treatment success rate at 3, 6, 9 months after treatment and adverse event rate

Countries

Japan

Contacts

Public ContactNaokatsu Ando

National Center for Global Health and Medicine Hospital AIDS Clinical Center

nandou@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026